<DOC>
	<DOCNO>NCT01093833</DOCNO>
	<brief_summary>The purpose study compare two continuous glucose sensor , one place subcutaneous ( skin ) one place intradermal ( skin ) 12-14 hour .</brief_summary>
	<brief_title>A Comparison Study Prototype Continuous Glucose Sensors Intradermal Subcutaneous Spaces</brief_title>
	<detailed_description>This single site , non-randomized study . The study consist screen visit ( Visit 1 ) , subject consent inclusion exclusion criterion confirm , experimental intervention ( Visit 2 ) follow-up visit ( Visit 3 ) . The experimental intervention base initial glucose clamp involve basal intravenous ( IV ) insulin infusion IV insulin bolus plus IV glucose infusion / IV glucose bolus require maintain euglycemic , hypoglycemic hyperglycemic plateau respectively 41 subject Type 1 Type 2 Diabetes . At end hour five study glucose clamp discontinue subject give standardized meal stimulate hyperglycemic excursion Each subject participate one experimental intervention . During glucose clamp intervention , subject 's blood glucose continuously monitor either mean Biostator frequent venous blood glucose measurement base standard lab method ( YSI STAT2300 analyzer ) , measure mean BD Technologies test device , Medtronic Guardian CGM . Once clamp discontinue Biostator discontinue well . During unclamped period meal subject BG monitor via YSI Glucose Analyzer , BD CGM sensor Medtronic Guardian CGM .</detailed_description>
	<criteria>Otherwise healthy male female subject Type 1 Type 2 diabetes mellitus Signed informed consent Age 18 65 year , inclusive Body mass index 19 30 kg/m² , inclusive HbA1c &lt; 11 % Uncontrolled arterial hypertension ( diastolic blood pressure &gt; 90 mm Hg and/or systolic blood pressure &gt; 160 mm Hg ) Impaired hepatic function measure alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ three time upper reference limit Impaired renal function measure creatinine &gt; 1.2 time upper limit normal . Severe acute disease , i.e . cardiac , pulmonary , gastrointestinal , hepatic , neurologic , infectious might interfere performance study , judge Investigator . Severe chronic disease , judge investigator Type 1 Diabetes Current use recent exposure medication opinion investigator could influence patient 's ability participate study performance test device . Known microvascular ( diabetic ) complication ( diabetic nonproliferative retinopathy ) , e.g . history laser coagulation , proliferative diabetic retinopathy , know diabetic nephropathy neuropathy require treatment Positive serology Hepatitis B , Hepatitis C HIV Pregnancy , breastfeed intention become pregnant use adequate contraceptive measure . Known current recent alcohol drug abuse Blood donation 500 ml within last three month Anticoagulant therapy Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Previous participation study involve GBPbased sensor Has take 4000 mg acetaminophen within past 24 hour ( i.e . 13 regular strength 8 extra strength Tylenol past 24 hour ) Any skin condition may judge affect study ( e.g. , bad sunburn , preexist dermatitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Blood glucose</keyword>
	<keyword>Continuous blood glucose monitoring</keyword>
	<keyword>CGM</keyword>
</DOC>